BCMAxCD3 Bispecific Antibody Elranatamab Is Effective in Patient Myeloma Relapsed after BCMA CAR-T

被引：2
|
作者：
Keller, Alana L. [1 ]
Parzych, Sarah E. [1 ]
Reiman, Lauren T. [1 ]
Walker, Zachary J. [1 ]
Forsberg, Peter A. [2 ]
Sherbenou, Daniel W. [1 ]
机构：
[1] Univ Colorado, Div Hematol, Anschutz Med Campus, Aurora, CO USA
[2] Univ Colorado, Div Hematol, Hlth Blood Disorders & Cell Therapies Ctr, Aurora, CO USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-187385
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
    Golubovskaya, Vita
    Zhou, Hua
    Li, Feng
    Berahovich, Robert
    Sun, Jinying
    Valentine, Michael
    Xu, Shirley
    Harto, Hizkia
    Sienkiewicz, John
    Huang, Yanwei
    Wu, Lijun
    BIOMEDICINES, 2021, 9 (10)
  • [32] Patient Awareness of CAR-T and Bispecific Antibody Treatments for Multiple Myeloma: Real-World Learnings and Disparities
    Adu, Yaw
    Das, Saurav
    Ailawadhi, Dhaani
    Fernandez, Andre
    Parrondo, Ricardo
    Roy, Vivek
    Sher, Taimur
    O'Connell, Sean
    Rasheed, Ahsan
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    BLOOD, 2023, 142
  • [33] Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma
    Rodriguez Otero, Paula
    Joseph, Nisha S.
    Kumar, Shaji K.
    Lee, Hans C.
    Leleu, Xavier
    Manier, Salomon
    Dimopoulos, Meletios A.
    Victoria Mateos, Maria
    Oriol, Albert
    Bumma, Naresh
    Gong, Weiying
    Roy, Pourab
    Lorenc, Karen Rodriguez
    Kroog, Glenn S.
    Sarkaria, Shawn M.
    BLOOD, 2022, 140 : 4444 - 4446
  • [34] Real-world comparison of overall survival between BCMA - bispecific and CAR-T therapies in multiple myeloma
    Song, J.
    Kim, G.
    Memon, R. S.
    Chi, K-Y.
    Chang, Y.
    Mehta, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S597 - S597
  • [35] Trial in progress: linvoseltamab, a BCMAxCD3 bispecific antibody, in a Phase 1b multi-cohort study of combination regimens for patients with relapsed/refractory multiple myeloma
    Rodriguez-Otero, Paula
    Joseph, Nisha
    Kumar, Shaji
    Leleu, Xavier
    Manier, Salomon
    Dimopoulos, Meletios
    Mateos, Maria-Victoria
    Oriol, Albert
    Bumma, Naresh
    Gong, Weiying
    Roy, Pourab
    Lorenc, Karen Rodriguez
    Kroog, Glenn
    Sarkaria, Shawn
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S60 - S60
  • [36] The Investigation of Antitumor Effect of Humanized Bispecific BCMA/CD38 CAR-T Cells on Multiple Myeloma
    Chen, Zhaoqi
    Lu, Yang
    Xu, Yingxi
    Qiu, Shaowei
    Gu, Runxia
    Xing, Haiyan
    Tang, Kejing
    Tian, Zheng
    Rao, Qing
    Xiong, Dongsheng
    Wang, Min
    Wang, Jianxiang
    BLOOD, 2022, 140 : 7402 - 7403
  • [37] Characteristics of Clinicopathological Features of 17 Patients Who Had Relapsed Myeloma After Anti-BCMA CAR-T Therapy
    Lin, Pei
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S68 - S68
  • [38] Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy
    Fu, Bingjie
    Liu, Rui
    Gao, Gongzhizi
    Lin, Zujie
    He, Aili
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [39] Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma
    Lu Han
    Ji-Shuai Zhang
    Jian Zhou
    Ke-Shu Zhou
    Ben-Ling Xu
    Lin-Lin Li
    Bai-Jun Fang
    Qing-Song Yin
    Xing-Hu Zhu
    Hu Zhou
    Xu-Dong Wei
    Hong-Chang Su
    Bing-Xiang Zhang
    Ya-Nan Wang
    Bin Xiang
    Quan-Li Gao
    Yong-Ping Song
    Leukemia, 2021, 35 : 3002 - 3006
  • [40] Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma
    Tacchetti, Paola
    Talarico, Marco
    Barbato, Simona
    Pantani, Lucia
    Mancuso, Katia
    Rizzello, Ilaria
    Zamagni, Elena
    Cavo, Michele
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (06) : 379 - 395
12345